importance of genetics in prostate cancer risk. It has been estimated that up to 40% of prostate cancers diagnosed may be attributed to one or more gene variants or mutations. 7 However, the field of prostate cancer genetics has been challenged by both the clinical and genetic heterogeneity of the disease as well as the high rate of sporadic cases.
Genome-wide association studies (GWAS) have resulted in the discovery of >100 common genetic variants associated with prostate cancer. GWAS single nucleotide polymorphisms (or SNPs) explain some of the familial clustering of disease, but in aggregate these variants only account for ∼30% of the familial risk. 8, 9 It is unknown how many of these common variants are actually tagging lesscommon, yet highly penetrant, coding variants. The declining cost of next-generation sequencing (NGS) over the past few years has made sequencing coding regions of the genome a feasible strategy for the identification of rare mutations.
As with most cancers, an earlier age at onset of prostate cancer, with or without a family history, is also an important indicator of the influence of inherited susceptibility. 10 As proof, men with early- (Qiagen, Germantown MD).
| Bioinformatics
Analysis of data was performed using the GeneRead Targeted 
| RESULTS
Of the 96 samples selected for sequencing, 66 were from UM and 30
were from KCI. Clinical characteristics of the cases are summarized in Far less is known of the role of BRIP1 and prostate cancer risk specifically, although the gene interacts with BRCA1 playing a role in DNA damage repair. 38, 39 BRIP1 is implicated in Fanconi anemia, a rare autosomal recessive disorder, associated with an increased risk for acute myeloid leukemia and other solid tumors, including breast, and prostate cancer. [40] [41] [42] [43] In a recently published series of 692 men with metastatic prostate cancer, one truncating mutation in BRIP1 was observed. 17 Our own work identified seven missense variants in BRIP1 among 94 individuals with hereditary prostate cancer but no protein truncating mutations were observed. 44 In this study, we also discovered two germline missense variants in ATM and one in PMS2 that are rare and predicted to be pathogenic cancer including lethal forms of the disease. 17, 45, 46 With the exception of BRCA2, it is the most commonly mutated DNA repair gene in men with lethal disease. 17, 46 The PMS2 (or post-meiotic segregation 2) gene functions in mismatch repair and is suggested to protect against prostate cancer progression through promotion of apoptosis in cancer cells. 47 It has also been shown that a reduction or loss of the PMS2 protein is associated with poorer differentiation of prostate tumors. 
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